Kim Bohyun, Kim Gilhyang, Song Boram, Lee Cheol, Park Jeong Hwan, Moon Kyung Chul
Department of Pathology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Department of Pathology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Dis Markers. 2016;2016:8463731. doi: 10.1155/2016/8463731. Epub 2016 Mar 10.
HER2 overexpression has been reported in a minority of urothelial carcinomas, but little is known about HER2 protein expression and gene alterations in plasmacytoid urothelial carcinoma, a rare and aggressive variant. The aim of this study was to clarify the HER2 status in plasmacytoid urothelial carcinomas.
Six cases of plasmacytoid urothelial carcinoma were included, in which we evaluated HER2 protein expression by immunohistochemistry (IHC) and HER2 gene amplification by fluorescence in situ hybridization (FISH).
The patients' ages ranged from 57 to 83 years (mean age, 71 years). Five patients were male and one was female. The ratio of the plasmacytoid component ranged from 30% to 100% (mean, 77%). HER2 expression score was 3+ in 4 cases, 2+ in one case, and negative in one case. HER2 gene amplification was positive in 3 cases, of which 2 cases showed a 3+ HER2 IHC score but one case was negative for HER2 IHC. Another 2 cases showed equivocal HER2 FISH results, and one remaining case was negative for HER2 FISH.
Our observation that plasmacytoid urothelial carcinomas frequently demonstrated HER2 protein overexpression provides supporting evidence that HER2 may be a potential therapeutic target for plasmacytoid urothelial carcinoma.
据报道，少数尿路上皮癌存在HER2过表达，但对于浆细胞样尿路上皮癌（一种罕见且侵袭性的变异型）中HER2蛋白表达和基因改变知之甚少。本研究的目的是阐明浆细胞样尿路上皮癌中的HER2状态。
纳入6例浆细胞样尿路上皮癌病例，通过免疫组织化学（IHC）评估HER2蛋白表达，并通过荧光原位杂交（FISH）检测HER2基因扩增。
患者年龄在57至83岁之间（平均年龄71岁）。5例为男性，1例为女性。浆细胞样成分的比例在30%至100%之间（平均77%）。HER2表达评分4例为3+，1例为2+，1例为阴性。HER2基因扩增3例为阳性，其中2例HER2 IHC评分为3+，但1例HER2 IHC为阴性。另外2例HER2 FISH结果不明确，其余1例HER2 FISH为阴性。
我们观察到浆细胞样尿路上皮癌经常表现出HER2蛋白过表达，这为HER2可能是浆细胞样尿路上皮癌的潜在治疗靶点提供了支持证据。
